Mizuho Rates Assembly Biosciences (ASMB) buy, $45 Price Target

Mizuho maintains a buy rating for Assembly Biosciences with a $45 price target, a 84.12% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 22, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Mizuho rated Assembly Biosciences, Inc. ($ASMB) "buy" with a $45 price target on June 15, 2026.

Since the rating, $ASMB is up 7.8% after 1 week, up 14.5% after 1 month and down 13.9% to date (from the $23.34 close on Jun 15, 2026).

ASMB Assembly Biosciences, Inc.

$20.09 -40.47% year to date

Daily close · Oct 16, 2026

Key Points

Mizuho reiterated its buy rating on Assembly Biosciences, Inc. (NasdaqGS: ASMB) with a price target of $45, as of June 15, 2026.
Mizuho's $45 price target implies 84.12% upside from Assembly Biosciences, Inc.'s ($ASMB) current $24.44 share price.
Shares of ASMB are trading at $22.96, with a market cap of $462.5 million and a P/E ratio of 291.75.
Insiders recently bought shares, and analysts maintain strong buy ratings, reflecting continued confidence in the company's prospects.

Get $ASMB trade alerts by text

We text you when insiders, Congress or big funds trade $ASMB. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Assembly Biosciences, Inc. alert may contain errors. Disclosures

Mizuho has reiterated its buy rating for Assembly Biosciences, Inc. (NasdaqGS: ASMB) as of June 15, 2026. The firm set a price target of $45 for the stock, which is currently trading at $22.96.

What Changed in Mizuho's Assembly Biosciences Position

Mizuho's analyst Salim Syed maintained the buy rating for Assembly Biosciences, suggesting confidence in the company's future performance. The price target of $45 indicates potential upside from the current trading price.

Other Institutional Activity in Assembly Biosciences

Among Assembly Biosciences' institutional investors, Janus Henderson Group PLC increased its holdings by 11,384 shares, bringing its total to 849,309 shares valued at approximately $23.48 million. In contrast, other major holders like Gilead Sciences, Inc., Farallon Capital Management LLC, and RA Capital Management, L.P. did not change their positions, holding their respective shares steady.

Assembly Biosciences, Inc. Stock Down 2.1%

Shares of Assembly Biosciences, Inc. trade on the NasdaqGS under the ticker ASMB. The stock is priced at $22.96, with a market capitalization of about $462.5 million. It has a P/E ratio of 291.75, indicating the stock is priced high relative to its earnings. The 52-week range for ASMB is between $16.50 and $39.71. The company has a beta of 1.085, suggesting moderate volatility compared to the market.

12-month forecast

$ASMB price target

Assembly Biosciences, Inc. daily closes and this analyst's $45 target. Not advice.

Recent Earnings

Assembly Biosciences reported revenue of $71.1 million, although it experienced a revenue decline of 12.8%. The company's net margin stands at -8.98%, with a return on equity of -5.66%. The next earnings report is expected on August 6, 2025.

Insider Buying and Selling at Assembly Biosciences, Inc.

On June 4, 2026, several insiders, including John McHutchison, Susan Mahony, Anthony Altig, Michael Houghton, Gina Consylman, and Lisa Johnson-Pratt, each purchased 8,000 shares of Assembly Biosciences. These transactions were not part of a pre-planned trading program, indicating a personal investment in the company's future.

Analysts Set New Price Targets

On June 15, 2026, Mizuho maintained its buy rating on Assembly Biosciences with a $45 price target. Other analysts, including Guggenheim and HC Wainwright & Co., also maintain buy ratings with targets ranging from $43 to $50. The consensus among analysts is a strong buy, with a mean price target of $50.

About Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company focused on developing therapies for viral diseases. Headquartered in South San Francisco, California, the company is led by CEO Jason A. Okazaki. It employs 73 people and is engaged in developing treatments for conditions like genital herpes and hepatitis. The company's pipeline includes several candidates in various stages of clinical trials.

Bottom Line

Mizuho's reiteration of a buy rating for Assembly Biosciences with a $45 target underscores continued analyst confidence in the company. Despite recent revenue challenges, insider buying and strong institutional interest suggest positive sentiment. As always, it's important to remember that 13F filings and analyst reports are backward-looking and may not reflect current conditions.